Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan).

导出 LinkOut

翻译打印收藏纠错

第一作者： Ashley L,Eadie

第一单位： Department of Pharmacology, Faculty of Medicine, Dalhousie University, Saint John, New Brunswick, Canada.

作者： Ashley L,Eadie ^[1] ; Keith R,Brunt ^[1] ; Matthew,Herder ^[2]

作者单位： Department of Pharmacology, Faculty of Medicine, Dalhousie University, Saint John, New Brunswick, Canada. ^[1] Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. ^[2] Health Law Institute, Schulich School of Law, Dalhousie University, Halifax, Nova Scotia, Canada. ^[3]

关键词 NT-proBNP PARADIGM-HF PARAGON-HF pediatric heart failure postmarketing requirements sex differences

主题词联苯化合物(Biphenyl Compounds);药物批准(Drug Approval);复方合剂(Drug Combinations);人类(Humans);美国(United States);美国食品和药物管理局(United States Food and Drug Administration)

DOI 10.1002/prp2.794

PMID 34087050

发布时间 2023-11-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Pharmacology research & perspectives

2021年9卷3期

e00794页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan).

Pharmacology research & perspectives

相似文献

Pharmacology research & perspectives

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan).

Pharmacology research & perspectives

相似文献

Pharmacology research & perspectives

相关期刊

检索历史清除